For Q1 FY2026 ended March 31, 2026, DexCom reported revenue of $1,191.9 million, up 15.0% year-over-year. Net income was $199.5 million, an increase of 89.3% from the prior year. Operating income rose 90.9% to $255.3 million, and diluted EPS grew 88.9% to $0.51. The company held $1,118.2 million in cash and had total equity of $2,956.9 million, with no long-term debt reported.
•Revenue increased 15.0% YoY to $1,191.9 million.
•Net income surged 89.3% to $199.5 million.
•Diluted EPS rose 88.9% to $0.51.
•Cash and equity stood at $1,118.2 million and $2,956.9 million, respectively, with no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
DexCom, Inc., a medical device company focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and globally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system.
Its portfolio also includes Dexcom G6, a CGM system, Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions, Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, Dexcom Share, a remote monitoring system, and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. Incorporated in 1999, the company is headquartered in San Diego, California.
What does DexCom, Inc. (DXCM) do and what are its main products?
DexCom, Inc. is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for managing diabetes and metabolic health. Its main products include the Dexcom G7 and G7 15 Day, an integrated CGM system, and the Dexcom G6, a CGM system that replaces fingerstick blood glucose testing for diabetes treatment decisions. The company also offers Dexcom ONE+, Stelo (a biosensor for adults with prediabetes and Type 2 diabetes not using insulin), and the Dexcom Share remote monitoring system along with the Dexcom Follow application. These products are marketed directly to endocrinologists, physicians, and diabetes educators.
On which stock exchange is DexCom (DXCM) listed and what is its trading currency?
DexCom, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol DXCM. The company's shares are traded in United States Dollars (USD), which is the official currency of the United States. As a US-based company listed on a major US exchange, its stock is primarily traded in USD, making it accessible to investors in the US and globally through brokers that support USD trading.
What sector and industry does DexCom (DXCM) operate in?
DexCom, Inc. operates in the Healthcare sector, specifically within the Medical Devices industry. This means the company is involved in developing and manufacturing medical equipment and technologies used for diagnosis, monitoring, and treatment of medical conditions. In DexCom's case, its focus is on continuous glucose monitoring systems for diabetes care, which falls under the broader category of medical devices that help patients manage chronic conditions.
Where is DexCom (DXCM) headquartered and what markets does it serve?
DexCom, Inc. is headquartered in San Diego, California, United States. The company was incorporated in 1999 and serves both the United States and global markets. Its products are marketed directly to endocrinologists, physicians, and diabetes educators, indicating a focus on healthcare professionals who prescribe or recommend diabetes management tools. While the company has a global presence, its headquarters and primary operations are based in the US.
How does DexCom (DXCM) generate revenue through its product portfolio?
DexCom generates revenue primarily by selling its continuous glucose monitoring (CGM) systems and related accessories. Its portfolio includes the Dexcom G7, G7 15 Day, Dexcom G6, Dexcom ONE+, and Stelo, each targeting different patient segments. The company also offers the Dexcom Share remote monitoring system and Dexcom Follow app, which may generate revenue through device sales or subscription services. By marketing directly to healthcare providers, DexCom aims to drive adoption of its CGM technology among patients with diabetes and metabolic health conditions, creating recurring revenue from sensor and transmitter replacements.